CONCERT's over: Pfizer and Medivation drop Alzheimer's candidate Dimebon

Pfizer and Medivation have dropped all further development of Dimebon (latrepirdine) after it failed to reach the two primary endpoints in the Phase III CONCERT trial in Alzheimer's disease. There had once been high hopes for the candidate, but disappointing results from earlier studies in Alzheimer's and Huntington's disease meant that this result had been widely anticipated.

The CONCERT trial examined the use of Dimebon when added to ongoing treatment with Pfizer/Eisai's AChE inhibitor Aricept (donepezil) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

HHS mRNA Vaccine Wind-Down Has Limited Impact (And One Contract Isn’t Even mRNA)

06 Aug 2025

• By Alaric DeArment

The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.